- Home
- ANVS vs PMVP Comparison
ANVS vs PMVP Comparison
Compare ANVS & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- PMVP
- Stock Information
- Founded
- ANVS 2008
- PMVP 2013
- Country
- ANVS United States
- PMVP United States
- Employees
- ANVS N/A
- PMVP N/A
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- PMVP Medicinal Chemicals and Botanical Products
- Sector
- ANVS Health Care
- PMVP Health Care
- Exchange
- ANVS Nasdaq
- PMVP Nasdaq
- Market Cap
- ANVS 110.4M
- PMVP 85.5M
- IPO Year
- ANVS 2020
- PMVP 2020
- Fundamental
- Price
- ANVS $9.57
- PMVP $1.65
- Analyst Decision
- ANVS Strong Buy
- PMVP Strong Buy
- Analyst Count
- ANVS 6
- PMVP 4
- Target Price
- ANVS $29.67
- PMVP $5.75
- AVG Volume (30 Days)
- ANVS 341.4K
- PMVP 185.0K
- Earning Date
- ANVS 11-06-2024
- PMVP 11-07-2024
- Dividend Yield
- ANVS N/A
- PMVP N/A
- EPS Growth
- ANVS N/A
- PMVP N/A
- EPS
- ANVS N/A
- PMVP N/A
- Revenue
- ANVS N/A
- PMVP N/A
- Revenue This Year
- ANVS N/A
- PMVP N/A
- Revenue Next Year
- ANVS N/A
- PMVP N/A
- P/E Ratio
- ANVS N/A
- PMVP N/A
- Revenue Growth
- ANVS N/A
- PMVP N/A
- 52 Week Low
- ANVS $4.53
- PMVP $1.33
- 52 Week High
- ANVS $22.49
- PMVP $3.47
- Technical
- Relative Strength Index (RSI)
- ANVS 58.70
- PMVP 60.86
- Support Level
- ANVS $9.00
- PMVP $1.63
- Resistance Level
- ANVS $10.54
- PMVP $1.69
- Average True Range (ATR)
- ANVS 0.81
- PMVP 0.07
- MACD
- ANVS 0.12
- PMVP 0.01
- Stochastic Oscillator
- ANVS 74.57
- PMVP 52.65
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.